{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T23:12:24Z","timestamp":1778368344503,"version":"3.51.4"},"reference-count":42,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014554","name":"Janssen Inc.","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,6,26]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objectives of this study were to describe the demographic profile and baseline disease characteristics of patients with psoriatic arthritis (PsA) treated with either infliximab (IFX), subcutaneous golimumab (GLM) or ustekinumab (UST) treatment in Canadian routine care setting along with assessing long-term effectiveness and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with PsA were enrolled into the Biologic Treatment Registry Across Canada registry (ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00741793\">NCT00741793<\/jats:ext-link>\n                      ) from 2005 to 2017. The study visits occurred at study enrolment (baseline) and every 6 months thereafter. Effectiveness was assessed by changes in disease parameters (joint counts, Psoriasis Area Severity Index (PASI), Health Assessment Questionnaire, patient\/physician global, minimal disease activity, enthesitis, dactylitis, erythrocyte sedimentation rate, C reactive protein). Improvements from baseline were explored with the paired t-test and the McNemar\u2019s test. Safety was evaluated by assessing the incidence of adverse events (AEs) and drug survival rates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 111 IFX-treated, 281 GLM-treated and 70 UST-treated patients were enrolled. Most baseline disease parameters remained similar over time in all three cohorts. UST-treated patients had lower mean baseline Disease Activity Score in 28 joints CRP, swollen joint based on 28 joints and higher PASI compared with patients treated with GLM. Treatment with IFX, GLM and UST was associated with significant improvements in all disease parameters over time (p&lt;0.001) from baseline up to 84, 84 and 40 months, respectively.<\/jats:p>\n                    <jats:p>AEs were reported for 74.8%, 69.8% and 52.9% (138, 114 and 115 events\/100 patient-years (PYs)) covering 325, 567 and 87 years of exposure for IFX-treated, GLM-treated and UST-treated patients, respectively. Severe AEs were reported in 19.8%, 8.5% and 5.7% (8.8, 7.2 and 8.0 events\/100 PYs) in IFX-treated, GLM-treated and UST-treated patients, respectively. The proportion of patients who discontinued treatment were 63.1%, 50.9% and 50.0%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IFX, GLM and UST treatment significantly reduced disease activity and improved functionality in patients with PsA followed by routine clinical practice and had a safety profile similar to that previously reported in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial results\" xlink:href=\"NCT00741793\">NCT00741793<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-036245","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T09:39:56Z","timestamp":1597397996000},"page":"e036245","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct00741793","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00741793","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct00741793","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Proton","family":"Rahman","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regan","family":"Arendse","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed","family":"Khraishi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalton","family":"Sholter","sequence":"additional","affiliation":[{"name":"Faculty of Medicine & Dentistry - Medicine Dept, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maqbool","family":"Sheriff","sequence":"additional","affiliation":[{"name":"Nanaimo, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[{"name":"JSS Research Inc, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen J","family":"Lehman","sequence":"additional","affiliation":[{"name":"Medical Affairs, Janssen Inc, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-3328","authenticated-orcid":false,"given":"Francois","family":"Nantel","sequence":"additional","affiliation":[{"name":"Medical Affairs, Janssen Inc, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"2025121406543961000_10.8.e036245.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.40.4.366"},{"key":"2025121406543961000_10.8.e036245.2","first-page":"1499","article-title":"Prevalence of psoriatic arthritis in Italian psoriatic patients","volume":"22","author":"Salvarani","year":"1995","journal-title":"J Rheumatol"},{"key":"2025121406543961000_10.8.e036245.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/23.4.246"},{"key":"2025121406543961000_10.8.e036245.4","doi-asserted-by":"crossref","first-page":"ii74","DOI":"10.1136\/ard.2004.030783","article-title":"Psoriatic arthritis therapy: NSAIDs and traditional DMARDs","volume":"64 Suppl 2","author":"Nash","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025121406543961000_10.8.e036245.5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5312\/wjo.v5.i4.537","article-title":"Psoriatic arthritis: epidemiology, diagnosis, and treatment","volume":"5","author":"Liu","year":"2014","journal-title":"World J Orthop"},{"key":"2025121406543961000_10.8.e036245.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.03.004"},{"key":"2025121406543961000_10.8.e036245.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"key":"2025121406543961000_10.8.e036245.8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1590\/S0482-50042013000300002","article-title":"Recommendations for the management and treatment of psoriatic arthritis","volume":"53","author":"Carneiro","year":"2013","journal-title":"Rev Bras Reumatol"},{"key":"2025121406543961000_10.8.e036245.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"2025121406543961000_10.8.e036245.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2025121406543961000_10.8.e036245.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767"},{"key":"2025121406543961000_10.8.e036245.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204902"},{"key":"2025121406543961000_10.8.e036245.13","doi-asserted-by":"publisher","DOI":"10.3310\/hta15140"},{"key":"2025121406543961000_10.8.e036245.14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2016.1139453","article-title":"Psoriatic arthritis: complexities, comorbidities and implications for the clinic","volume":"12","author":"Haroon","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"2025121406543961000_10.8.e036245.15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10067-018-4332-7","article-title":"Role of comorbidities in spondyloarthritis including psoriatic arthritis","volume":"38","author":"Scriffignano","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025121406543961000_10.8.e036245.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew375"},{"key":"2025121406543961000_10.8.e036245.17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10067-019-04426-3","article-title":"Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry","volume":"38","author":"Kalyoncu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025121406543961000_10.8.e036245.18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000181"},{"key":"2025121406543961000_10.8.e036245.19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000880"},{"key":"2025121406543961000_10.8.e036245.20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/1346-8138.14834","article-title":"Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka university psoriasis registry","volume":"46","author":"Bayaraa","year":"2019","journal-title":"J Dermatol"},{"key":"2025121406543961000_10.8.e036245.21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41927-018-0034-7","article-title":"Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry","volume":"2","author":"Kavanaugh","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2025121406543961000_10.8.e036245.22","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/acr.22290","article-title":"Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry","volume":"66","author":"Thorne","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2025121406543961000_10.8.e036245.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016619"},{"key":"2025121406543961000_10.8.e036245.24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/rheumatology\/key359","article-title":"Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab","volume":"58","author":"Coates","year":"2019","journal-title":"Rheumatology"},{"key":"2025121406543961000_10.8.e036245.25","unstructured":"Silverman ED . Canadian rheumatology association meeting Fairmont the Queen Elizabeth Montreal, Quebec, Canada. J Rheumatol 2019."},{"key":"2025121406543961000_10.8.e036245.26","first-page":"S1","article-title":"Abstracts, 21st PANLAR meeting","volume":"25","year":"2019","journal-title":"JCR: Journal of Clinical Rheumatology"},{"key":"2025121406543961000_10.8.e036245.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214822"},{"key":"2025121406543961000_10.8.e036245.28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fmed.2018.00246","article-title":"Classification and outcome measures for psoriatic arthritis","volume":"5","author":"Leung","year":"2018","journal-title":"Front Med"},{"key":"2025121406543961000_10.8.e036245.29","doi-asserted-by":"publisher","DOI":"10.1177\/2040622312459673"},{"key":"2025121406543961000_10.8.e036245.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150614"},{"key":"2025121406543961000_10.8.e036245.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009661"},{"key":"2025121406543961000_10.8.e036245.32","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025121406543961000_10.8.e036245.33","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22645"},{"key":"2025121406543961000_10.8.e036245.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209068"},{"key":"2025121406543961000_10.8.e036245.35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021082"},{"key":"2025121406543961000_10.8.e036245.36","first-page":"804","article-title":"Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry","volume":"35","author":"Manara","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025121406543961000_10.8.e036245.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140538"},{"key":"2025121406543961000_10.8.e036245.38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep423"},{"key":"2025121406543961000_10.8.e036245.39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq326"},{"key":"2025121406543961000_10.8.e036245.40","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073544"},{"key":"2025121406543961000_10.8.e036245.41","doi-asserted-by":"crossref","first-page":"rky042","DOI":"10.1093\/rap\/rky042","article-title":"Long-term effectiveness of tumour necrosis factor-\u03b1 inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study","volume":"2","author":"Clunie","year":"2018","journal-title":"Rheumatol Adv Pract"},{"key":"2025121406543961000_10.8.e036245.42","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1517\/14712598.2014.967211","article-title":"Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity","volume":"14","author":"Lories","year":"2014","journal-title":"Expert Opin Biol Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-036245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T14:54:53Z","timestamp":1765724093000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-036245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,13]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjopen-2019-036245"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-036245","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}